Yezan Munther Haddadin, Director at Outlook Therapeutics, Inc. (OTLK), bought 1,881 shares at $11.82 ($22K) on 2024-03-28, disclosed to the SEC on 2024-03-29.
Open-market purchase of $22k OTLK by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Something here stands out, but not much.
| Filing → |
| OTLK | BUY | 2022-10-11 | $43K | — | Filing → |
| OTLK | BUY | 2021-12-02 | $14K | — | Filing → |
| OTLK | BUY | 2021-04-20 | $18K | — | Filing → |